Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies

Genes and Cancer

Volumn 2, Issue 12, 2011, Pages 1097-1105

  Shibuya, Masabumi ^a,b,c  

^a JOBU UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

anti angiogenic therapy; neuronal degeneration; pro angiogenic therapy; tumor angiogenesis; VEGF; VEGF receptor

Indexed keywords

ANGIOGENESIS INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; CANCER THERAPY; DRUG TARGETING; GLIOBLASTOMA; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOSIS; TUMOR VASCULARIZATION;

MUS; TRIMERESURUS FLAVOVIRIDIS;

EID: 84868618639     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911423031     Document Type: Article

References (64)

1. Risau W.Mechanism of angiogenesis.Nature. 1997;386:671-4.
2. Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell. 1996;86:353-64.
3. Ferrara N,Kerbel RS.Angiogenesis as a therapeutic target.Nature. 2005;438:967-74.
4. Shibuya M.Role of VEGF-Flt receptor system in normal and tumor angiogenesis.Adv Cancer Res. 1995;67:281-316.
5. Shibuya M,Claesson-Welsh L.Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.Exp Cell Res. 2006;312:549-60.
6. Alitalo K,Carmeliet P.Molecular mechanisms of lymphangiogenesis in health and disease.Cancer Cell. 2002;1:219-27.
7. Hurwitz H,Fehrenbacher L,Novotny W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med. 2004;350:2335-42.
8. Sandler A,Gray R,Perry MC, et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med. 2006;355:2542-50.
9. Senger DR,Galli SJ,Dvorak AM, et al.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science. 1983;219:983-5.
10. Leung DW,Cachianes G,Kuang W-J, et al.Vascular endothelial growth factor is a secreted angiogenic mitogen.Science. 1989;246:1306-9.
11. Muller YA,Li B,Christinger HW,Wells JA,Cunningham BC,de Vos AM.Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site.Proc Natl Acad Sci U S A. 1997;94:7192-7.
12. Kiba A,Yabana N,Shibuya M.A set of loop-1 and -3 structures in the novel VEGF family member, VEGF-ENZ-7, is essential for the activation of VEGFR-2 signaling.J Biol Chem. 2003;278:13453-61.
13. Maes C,Carmeliet P,Moermans K, et al.Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.Mech Dev. 2002;111:61-73.
14. Pritchard-Jones RO,Dunn DB,Qiu Y, et al.Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma.Br J Cancer. 2007;97:223-30.
15. Lee S,Chen TT,Barber CL, et al.Autocrine VEGF signaling is required for vascular homeostasis.Cell. 2007;130:691-703.
16. Carmeliet P,Moons L,Luttun A, et al.Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.Nat Med. 2001;7:575-83.
17. Aase K,von Euler G,Li X, et al.Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect.Circulation. 2001;104:358-64.
18. Dhondt J,Peeraer E,Verheyen A, et al.Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons.FASEB J. Epub. 2011;:19.
19. McColl BK,Paavonen K,Karnezis T, et al.Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2.FASEB J. 2007;21:1088-98.
20. Lyttle DJ,Fraser KM,Fleming SB,Mercer AA,Robinson AJ.Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus.J Virol. 1994;68:84-92.
21. Ogawa S,Oku A,Sawano A,Yamaguchi S,Yazaki Y,Shibuya M.A novel type of vascular endothelial growth factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain.J Biol Chem. 1998;273:31273-82.
22. Meyer M,Clauss M,Lepple-Wienhues A, et al.A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.EMBO J. 1999;18:363-74.
23. Wise LM,Veikkola T,Mercer AA, et al.Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1.Proc Natl Acad Sci U S A. 1999;96:3071-6.
24. Jove R,Hanafusa H.Cell transformation by the viral src oncogene.Annu Rev Cell Biol. 1987;3:31-56.
25. Takahashi H,Hattori S,Iwamatsu A,Takizawa H,Shibuya M.A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1.J Biol Chem. 2004;279:46304-14.
26. Sawano A,Takahashi T,Yamaguchi S,Aonuma T,Shibuya M.Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor (PlGF), which is related to vascular endothelial growth factor (VEGF).Cell Growth Diff. 1996;7:213-21.
27. Takahashi T,Ueno H,Shibuya M.VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells.Oncogene. 1999;18:2221-30.
28. Takahashi T,Yamaguchi S,Chida K,Shibuya M.A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells.EMBO J. 2001;20:2768-78.
29. Sakurai Y,Ohgimoto K,Kataoka Y,Yoshida N,Shibuya M.Essential role of Flk-1 (vascular endothelial growth factor receptor-2) tyrosine residue-1173 in vasculogenesis in mice.Proc Natl Acad Sci U S A. 2005;102:1076-81.
30. Lawson ND,Mugford JW,Diamond BA,Weinstein BM.Phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development.Genes Dev. 2003;7:1346-51.
31. Xiong Y,Huo Y,Chen C, et al.Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathways.J Biol Chem. 2009;284:23217-24.
32. Sase H,Watabe T,Kawasaki K,Miyazono K,Miyazawa K.VEGFR2-PLCgamma1 axis is essential for endothelial specification of VEGFR2+ vascular progenitor cells.J Cell Sci. 2009;122:3303-11.
33. Matsumoto T,Bohman S,Dixelius J, et al.VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis.EMBO J. 2005;24:2342-53.
34. Sawano A,Takahashi T,Yamaguchi S, et al.The phosphorylated 1169-tyrosine containing region of Flt-1 kinase (VEGFR-1) is a major binding site for PLCγ.Biochem Biophys Res Commun. 1997;238:487-91.
35. Wang F,Yamauchi M,Muramatsu M,Osawa T,Tsuchida R,Shibuya M.RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway.J Biol Chem. 2011;286:9097-106.
36. Fong GH,Rossant J,Gertsentein M,Breitman ML.Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.Nature. 1995;376:66-70.
37. Hiratsuka S,Minowa O,Kuno J,Noda T,Shibuya M.Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.Proc Natl Acad Sci U S A. 1998;95:9349-54.
38. Kerber M,Reiss Y,Wickersheim A, et al.Flt-1 signaling in macrophages promotes glioma growth in vivo.Cancer Res. 2008;68:7342-51.
39. Muramatsu M,Yamamoto S,Osawa T,Shibuya M.VEGF-1 signaling promotes mobilization of macrophage-lineage cells from bone marrow and stimulateolid tumor growth.Cancer Res. 2010;70:8211-21.
40. Hiratsuka S,Nakamura K,Iwai S, et al.MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung specific metastasis.Cancer Cell. 2002;2:289-300.
41. Murakami M,Iwai S,Hiratsuka S, et al.Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocyte/macrophages.Blood. 2006;108:1849-56.
42. Kaplan RN,Riba RD,Zacharoulis S, et al.VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.Nature. 2005;438:820-7.
43. Wu Y,Hooper AT,Zhong Z, et al.The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.Int J Cancer. 2006;119:1519-29.
44. Shibuya M,Yamaguchi S,Yamane A, et al.Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.Oncogene. 1990;5:519-24.
45. Kendall RL,Thomas KA.Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proc Natl Acad Sci U S A. 1993;90:10705-9.
46. Kondo K,Hiratsuka S,Subbalakshmi E,Matsushime H,Shibuya M.Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors.Gene. 1998;208:297-305.
47. Maynard SE,Min JY,Merchan J, et al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.J Clin Invest. 2003;111:649-58.
48. Koga K,Osuga Y,Yoshino O, et al.Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia.J Clin Endocrinol Metab. 2003;88:2348-51.
49. Levine RJ,Maynard SE,Qian C, et al.Circulating angiogenic factors and the risk of preeclampsia.N Engl J Med. 2004;350:672-83.
50. Ambati BK,Nozaki M,Singh N, et al.Corneal avascularity is due to soluble VEGF receptor-1.Nature. 2006;443:993-7.
51. Peak SJ,Levin VA.Role of bevacizumab therapy in the management of glioblastoma.Cancer Manag Res. 2010;2:97-104.
52. Wada S,Tsunoda T,Baba T, et al.Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2.Cancer Res. 2005;65:4939-46.
53. Van de,Veire S,Stalmans I,Heindryckx F, et al.Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.Cell. 2010;141:178-90.
54. Bais C,Wu X,Yao J, et al.PlGF blockade does not inhibit angiogenesis during primary tumor growth.Cell. 2010;141:166-77.
55. Kim KJ,Li B,Winer J, et al.Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.Nature. 1993;362:841-4.
56. Fukumura D,Jain RK.Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.Microvasc Res. 2007;74:72-84.
57. Zuniga RM,Torcuator R,Jain R, et al.Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.J Neurooncol. 2009;91:329-36.
58. Casanovas O,Hicklin DJ,Bergers G,Hanahan D.Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.Cancer Cell. 2005;8:299-309.
59. Osawa T,Muramatsu M,Watanabe M,Shibuya M.Hypoxia and low nutrition double stress induces aggressiveness in a murine model of melanoma.Cancer Sci. 2009;100:844-51.
60. Oosthuyse B,Moons L,Storkebaum E, et al.Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.Nat Genet. 2001;28:131-8.
61. Storkebaum E,Lambrechts D,Dewerchin M, et al.Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.Nat Neurosci. 2005;8:85-92.
62. Detmar M,Brown LF,Schon MP, et al.Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice.J Invest Dermatol. 1998;111:1-6.
63. Kiba A,Sagara H,Hara T,Shibuya M.VEGFR-2-specific ligand VEGF-E induces non- edematous hyper-vascularization in mice.Biochem Biophys Res Commun. 2003;301:371-7.
64. Zheng Y,Watanabe M,Kuraishi T,Hattori S,Kai C,Shibuya M.Chimeric VEGF-ENZ7/PlGF specifically binding to VEGFR-2 accelerates skin wound healing via enhancement of neovascularization.Arterioscler Thromb Vasc Biol. 2007;27:503-11.